(Q37993945)

26 August 2017

Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus (English)

1 reference

26 August 2017

0 references

1 reference

1

1 reference

26 August 2017

J Speight

2

0 references

publication date

17 April 2012

1 reference

Diabetes, Obesity and Metabolism

26 August 2017

1 reference

26 August 2017

14

1 reference

26 August 2017

10

1 reference

26 August 2017

882-892

1 reference

Medication taking and diabetes: a systematic review of the literature

26 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

DPP-4 inhibitors: what may be the clinical differentiators?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Not all roads lead to Rome-a review of quality of life measurement in adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Patient perceptions of diabetes and diabetes therapy: assessing quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Patient-assessed health outcome measures for diabetes: a structured review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

The Diabetes Treatment Satisfaction Questionnaire: a cross-cultural South African perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Psychometric validation and use of a novel diabetes in-patient treatment satisfaction questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Psychometric properties and responsiveness of the Turkish version of the Diabetes Treatment Satisfaction Questionnaire (s) on a sample of diabetics of three consecutive monitoring periods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Feedback on the FDA's February 2006 draft guidance on Patient Reported Outcome (PRO) measures from a developer of PRO measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Development of a brief measure to assess quality of life in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Assessing weight-related quality of life in obese persons with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

The relationship between health-related quality of life and weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Impact of weight loss and regain on quality of life: mirror image or differential effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Liraglutide: effects beyond glycaemic control in diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01595.X

10.1111/J.1463-1326.2012.01595.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22420869